XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2022
Summary of Significant Accounting Policies  
Schedule of disaggregation of revenue by major source

Three Months Ended March 31,

    

2022

    

2021

Biopharma/Pharma

$

43,011

$

42,393

Animal Health

 

6,794

 

8,997

Reproductive Medicine

2,497

1,894

Total revenues

$

52,302

$

53,284

Schedule of geographical revenues, by origin

Three Months Ended March 31,

    

2022

    

2021

Americas

$

27,878

$

27,734

Europe, the Middle East and Africa (EMEA)

 

16,187

 

14,208

Asia Pacific (APAC)

 

8,237

 

11,342

Total revenues

$

52,302

$

53,284

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended March 31, 

    

2022

    

2021

Net loss

$

(13,404)

$

(3,527)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,000)

 

(2,196)

Net loss attributable to common shareholders

$

(15,404)

$

(5,723)

Weighted average common shares outstanding – basic and diluted

49,660,579

43,804,483

Basic and diluted net loss per share

$

(0.31)

$

(0.13)

Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended March 31, 

    

2022

    

2021

Stock options

4,699,476

 

6,149,186

Restricted stock units

693,887

304,157

Series C convertible preferred stock

5,497,939

5,283,411

Conversion of 2026 Senior Notes

3,422,780

Conversion of 2025 Senior Notes

599,954

 

4,810,002

14,914,036

 

16,546,756